Miguel Villanueva, MD

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma Chimeric antigen receptor (CAR) T-cell therapy has shown impressive efficacy in treating relapsed or refractory multiple myeloma. Nonetheless, its availability is substantially restricted by complex m...

In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma - The Lancet www.thelancet.com/journals/lan...

Antibiotic use: impact on the microbiome and cellular therapy outcomes
buff.ly/Awz7wZU #hemesky

In this 60-Second Journal Club, NEJM Editorial Fellow Abarna Pearl, MD, MPH, summarizes the BALANCE trial comparing antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. Read the full article and accompanying Research Summary: nej.md/3Z5bTJD

#MedSky #IDSky

Perforin is responsible for creating a channel/pore (punching a hole) between cytolytic lymphocytes, natural killer cells and CD8 T cells, and their target cells, allowing for the delivery of apoptosis-inducing granzyme proteins. buff.ly/YFitped #hemesky

No doubts #EHA is the best congress of hematology ever.

EHA 2025 Highlights: JNJ-5322 Trispecific Antibody in RRMM EHA 2025 highlights first-in-human results of JNJ-5322, a trispecific antibody with 100% ORR in naïve RRMM patients and favorable safety profile.

EHA Highlights: First-in-Human Study of Trispecific Antibody JNJ-5322 Shows Promising Activity in Relapsed/Refractory Multiple Myeloma

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA #EHA2025 #MM #RRMM

Risk of SMN Low After CAR-T Therapy: The risk of secondary #myeloid #neoplasms (SMNs) following #CD19 #CARTcell therapy may be lower than expected. According to a retrospective study, SMNs occurred in 2.5% of patients after treatment with CAR T-cell therapy.
#HemeSky

For patients undergoing CD19-directed #CARTcell therapy, #itacitinib prophylaxis effectively reduced the incidence and severity of #cytokine release syndrome (CRS), with just 17.4% of patients experiencing grade ≥2 CRS compared with 56.5% on placebo: ow.ly/9y5l50W4mYU
#HemeSky #MedSky

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T cell therapy Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

Results from an MD Anderson study identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 CAR T cell therapy.

How the findings offer insights on the best potential clinical pathways: spr.ly/60174rfXF #EndCancer

A recent meta-analysis in JAMA Network Open evaluated cardiovascular risks in 1,528 adults receiving CAR T-cell therapy for advanced blood cancers.

@jama.com

#Onco404 #Cancer #Kanser #Hematology #CardioOncology #CARTCellTherapy #MetaAnalysis #MedResearch #MedSky #OncSky

There are so many ways to rev up our immune response against cancer. Here, the oncolytic viruses
www.cell.com/cancer-cell/...

The New England Journal of Medicine Antibiotic Treatment for 7 or 14 Days for Bloodstream Infection A Research Summary based on The BALANCE Investigators | 10.1056/NEJMoa2404991 | Published on November 20, 2024 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

In the BALANCE trial, patients with bacteremia were assigned to 7 or 14 days of appropriate antimicrobial therapy, and 7 days of therapy was found to be noninferior to 14 days. Full trial results and Research Summary: nej.md/3Z5bTJD

#MedSky #CriticalCare #IDSky

TB drug targets

Today is World TB day. Here's a recent comprehensive review on therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease
www.nature.com/articles/s41...
rdcu.be/eeQ0m

The Pharmaceutical approach of obesity in children is a complete mistake, terrible results in a multi factorial disease.

Come together, right now The chaos, conflicting information, firings, and hurtful rhetoric of the Trump administration’s approach to science over the past month are causing anxiety, grief, and concern for the scientific commu...

Come together, really hard times for the science. | Science www.science.org/doi/10.1126/...

Restoration of the #immune function as a complementary strategy to treat #CLL effectively. This approach aims to achieve dual disease control by targeting both malignant B-cell activity and the often-compromised immune system in #CLL patients.

Eggs?

Table. Stem Cell Donation Process and Short-Term Adverse Effects of Stem Cell Donation

Hematopoietic stem cell transplant is a critical treatment for various cancers and other conditions.

This JAMA Insights discusses the process of allogeneic stem cell donation, including donor selection, preparation, and potential risks and benefits.

ja.ma/40911K8

Cytomegalovirus (CMV) is the leading cause of infectious birth defects and linked to many other morbidities such as with transplantation. For the first time after >50 years of pursuit, a vaccine is in reach jci.org/articles/vie...

YouTube video by Willem Martinot It Is Your Life - a Charles Bukowski Poem

Del gran Bukowski "No leaders please" Esto de las fechas "especiales" si tienen algo de bueno (probablemente lo único) es que son recordatorio de gratitud, reflexión, y sobre todo, de re invención a diferentes niveles, al no tenerlo en cuenta todo pierde sentido...

youtu.be/PLauo0Qx48k?...

Excelente

Un documental desgarrador, extraordinario #NoOtherLand. Siempre en @filmin.es

Ayuso es todo lo malo que te puedas imaginar, todo.

Whooping cough

La contaminación mata. #AirPollution

eTable. Guideline Ratings

JAMA Clinical Guidelines Synopsis summarizes the 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. https://ja.ma/4guePp2

Outstanding review. #CART #Hematology @medsky.social

Image of podcast "JAMA Clinical Reviews."

Allogeneic stem cell transplant can be a life-saving therapy for pts w cancer or other conditions such as sickle cell disease. JAMA Fellow Hermioni Amonoo, harvardmed, joins JAMA Deputy Editor Kristin Walter to discuss allogeneic stem cell donation.

https://ja.ma/41tyj9b

Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months. The drug attaches to the lattice-like capsid proteins that shield the virus’s genetic material—a mechanism that could inspire other antivirals. Lenacapavir could help end the HIV/AIDS epidemic, but that will hinge on access for those who need it most.

Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.

Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn

De toda la vida